• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, May 11, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

COVID immunity lasts up to 8 months, new data reveals

Bioengineer by Bioengineer
December 22, 2020
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Real hope for longevity of COVID vaccinations

IMAGE

Credit: Monash University

Australian researchers have revealed – for the first time – that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.

The research is the strongest evidence for the likelihood that vaccines against the virus, SARS-CoV-2, will work for long periods.  Previously, many studies have shown that the first wave of antibodies to coronavirus wane after the first few months, raising concerns that people may lose immunity quickly.  This new work allays these concerns.

The study is the result of a multi-centre collaboration led by Associate Professor Menno van Zelm, from the Monash University Department of Immunology and Pathology,  with the Alfred Research Alliance between Monash University, The Alfred hospital and the Burnet Institute, and published today in the prestigious journal, Science Immunology. The publication reveals the discovery that specific cells within the immune system called memory B cells, “remembers” infection by the virus, and if challenged again, through re-exposure to the virus, triggers a protective immune response through rapid production of protective antibodies.

The researchers recruited a cohort of 25 COVID-19 patients and took 36 blood samples from them from Day 4 post infection to Day 242 post infection.

As with other studies – looking only at the antibody response – the researchers found that antibodies against the virus started to drop off after 20 days post infection.

However – importantly – all patients continued to have memory B cells that recognised one of two components of the SARS-CoV-2 virus, the spike and nucleocapsid proteins. These virus-specific memory B cells were stably present as far as eight months after infection.

According to Associate Professor van Zelm, the results give hope to the efficacy of any vaccine against the virus and also explains why there have been so few examples of genuine reinfection across the millions of those who have tested positive for the virus globally.

“These results are important because they show, definitively, that patients infected with the COVID-19 virus do in fact retain immunity against the virus and the disease,” he said.

“This has been a black cloud hanging over the potential protection that could be provided by any COVID-19 vaccine and gives real hope that, once a vaccine or vaccines are developed, they will provide long-term protection.”

###

Media Contact
Tania Ewing
[email protected]

Tags: Clinical TrialsDisease in the Developing WorldMedicine/HealthPublic HealthVaccines
Share13Tweet8Share2ShareShareShare2

Related Posts

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

May 11, 2026

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

May 10, 2026

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

May 10, 2026

Urdu Fall Risk Questionnaire Adapted for Elderly

May 10, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    840 shares
    Share 336 Tweet 210
  • New Study Reveals Plants Can Detect the Sound of Rain

    727 shares
    Share 290 Tweet 181
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    61 shares
    Share 24 Tweet 15
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.